Thomas Adamkiewicz to Pneumococcal Vaccines
This is a "connection" page, showing publications Thomas Adamkiewicz has written about Pneumococcal Vaccines.
Connection Strength
0.801
-
Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008 Mar; 121(3):562-9.
Score: 0.285
-
Yee ME, Abel L, Kalmus G, Patel A, Elmontser M, Bakshi N, Wang YF, Gonzalez MD, Adamkiewicz TV, Yildirim I, Lane PA. Clinical Features and Outcomes of Pneumococcal Bacteremia in Children With Sickle Cell Disease in the Pneumococcal Conjugate Vaccine Era. Pediatr Blood Cancer. 2025 Sep; 72(9):e31881.
Score: 0.236
-
Payne AB, Gierke R, Xing W, McGee L, Hulihan M, Adamkiewicz TV, Kobayashi M. Prevention of Invasive Pneumococcal Disease Among Black or African American Children With and Without Sickle Cell Disease in the United States After Introduction of 13-Valent Pneumococcal Conjugate Vaccine, 2005 Through 2019. Pediatr Blood Cancer. 2025 Mar; 72(3):e31467.
Score: 0.228
-
Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong WY, Wang WC. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003 Oct; 143(4):438-44.
Score: 0.052